Activation in Children and Adolescents Treated With Selective Serotonin Reuptake Inhibitors: A Weighty Reason?

Area of Science:

• Neuroscience
• Developmental Psychology
• Pediatric Pharmacology

Background:

• Activation is a behavioral adverse event associated with psychotropic medication use.
• High incidence in pediatric populations and childhood-onset neuropsychiatric disorders suggests a link to neurodevelopment.
• Limited research exists on developmental pharmacokinetic factors, like body weight, influencing activation in pediatric patients.

Purpose of the Study:

• To identify risk factors for activation in children and adolescents treated with selective serotonin reuptake inhibitors.
• To explore the relationship between activation and neurodevelopmental processes, considering factors like body weight.

Main Methods:

• Retrospective analysis of hospitalized pediatric patients.
• Inclusion of developmental factors, including body weight, in risk factor assessment.
• Focus on selective serotonin reuptake inhibitor (SSRI) treatment.

Main Results:

• Activation occurred in 20.9% of 139 participants (mean age 14 ± 2.3 years).
• Younger age (≤12 years) and comorbid autism spectrum disorder were significant risk factors for activation.
• No association was found between body weight and the risk of activation.

Conclusions:

• Findings support the hypothesis that activation is closely linked to brain development processes.
• Further longitudinal studies are recommended to investigate this relationship.
• Age and autism spectrum disorder are key considerations in pediatric psychotropic medication management.